Transcenta-B 06628 Prospectus Information

Company Overview

Stock Name	Transcenta-B
Stock Code	06628
Company Full Name	To be extracted
Industry	醫療保健
Principal Activities	主要從事研發、制造及商業化生物制藥。
Listing Date	2021-09-29
Listing Rules Era	Old Rules
Listing Rules Chapter	To be extracted
Weighted Voting Rights (WVR)	No
Registered Address (Mainland China)	中國江蘇省蘇州市星湖街218號生物納米園B6-501室
Business Address (Hong Kong)	To be extracted
Place of Incorporation	To be extracted
Listing Method	To be extracted
Listing Board	Main Board
Website	http://www.transcenta.com
Share Registrar	卓佳证券登记有限公司 (Tricor Investor Services Limited)
Registrar Contact	(852)2980 1333
A-Share/US Dual Listing	No data

Offering Information

Offering Mechanism	To be extracted
Offer Price	HK$ 16.00 / shares
Offer Price Range	To be extracted
Lot Size	To be extracted
Entry Threshold	To be extracted
Par Value	To be extracted
Offer Period	To be extracted
Global Offering Shares	To be extracted
HK Public Offer Shares (Initial)	To be extracted
Public Offer Lots (Initial)	To be extracted
International Placing Shares (Initial)	To be extracted
Offer Ratio	To be extracted
Total Shares Post-IPO	To be extracted
Greenshoe (Over-allotment Option)	To be confirmed
Stabilizing Manager (Greenshoe)	—
Cornerstone Share	69.6%
Clawback Tiers	To be extracted
Reallocation Option	To be confirmed
Total Global Offering Size	HK$ 258,112,000

Stock Connect Inclusion

HK Market Cap	---

26Q2 Regular Review
Inclusion Pathway	None
Est. Threshold	---
Analysis Result	无法确定入通路径

Valuation & Financials

Market Cap (at Offer Price)	To be extracted
Pre-IPO Valuation (Last Round)	Not disclosed
P/E Ratio	Not disclosed
Profit/Loss Status	To be extracted
Period-End Cash Balance	To be extracted
Listing Expenses	To be extracted
Listing Expenses / Funds Raised	To be extracted
Total Pre-IPO Investment	To be extracted

First Day Performance

First Day Close	HK$ 13.24
First Day Open	HK$ 13.0
First Day Change	-17.25%
First Day Volume	11079000.0
First Day Turnover	143255000.0

Use of Proceeds

Use of Proceeds	1、82%或約471.0百萬港元用于我們管線候選產品的研發、為進行中及計劃中的臨床及臨床前試驗、籌備注冊備案以及其他與商業化我們四款主打產品有關的步驟或活動撥資； 2、8%或約46.0百萬港元用于為擴充管線及開發技術的業務發展撥資； 3、10%或約57.4百萬港元用作一般營運資金及一般營運費用。

Underwriting Syndicate

Joint Sponsors (2)

GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 China International Capital Corporation Hong Kong Securities Limited CE AEN894

Overall Coordinators (4)

GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 China International Capital Corporation Hong Kong Securities Limited CE AEN894 BOCI ASIA LIMITED CE AET863 China Renaissance Securities (Hong Kong) Limited CE AZX839

Joint Bookrunners (4)

Joint Lead Managers (4)

Cornerstone Investors

#	Investor Name	Investment Amount	Shares Subscribed	% of Offer Shares	% of Total Shares	Lock-up Period	Est. Unlock Date
1	Aranda Investments Pte. Ltd.	33,032,000 HKD	—	5.12%	—	6 months	2022-03-29
2	LAV Amber Limited	52,856,000 HKD	—	8.19%	—	6 months	2022-03-29
3	QH Oil Investments LLC	165,200,000 HKD	—	25.60%	—	6 months	2022-03-29
4	中国国有企业结构调整基金股份有限公司	198,240,000 HKD	—	30.72%	—	6 months	2022-03-29

Directors & Management

Chairman	錢雪明
Company Secretary	梁君慧

No director data available.

Major Shareholders

Major Shareholders & Holdings	Yi Shi(15.84%);錢雪明及家族成員(13.09%);中國國有企業結構調整基金股份有限公司(8.85%);Success Link International L.P.(8.38%);淡馬錫控股(私人)有限公司(6.31%)

Transcenta-B 06628Prospectus Information